Introduced quarantine evoked a host of restrictions that affect the implementation of marketing plans of pharmaceutical companies. First of all, we are talking about contacts of pharmaceutical companies with healthcare specialists. For instance, at the moment all group activities on medical issues may be held only on-line.
In addition, a great deal of companies (including pharmaceutical ones) work remotely, resulting in the issues with adequate organization of such events on-line, as well as with remote communication with physicians (for example, substitution company representatives` visits with remote communication).
As we see in such situations, the most problematic are the following interaction aspects:
Moreover, there is a global trend for charitable support to healthcare facilities and physicians to fight against COVID-19 pandemic. Both international companies, and Ukrainian businesses allocate funds or purchases products toward this purpose on daily basis. As a result, there is increasing relevance of adequate documentation of charitable aid during a pandemic (in particular, in case of such support in the form of medicines and medical devices).
Improperly prepared documents with regard to the interaction with physicians, charitable aid, and service provision in general, may have negative consequences for companies, related to the violation of healthcare and anti-corruption, and tax laws of Ukraine.
All these issues can be solved with legal and field proven methods. We are happy to help in solving your issues and adequately respond to the new quarantine challenges for business.
For all pressing issues on legal adjustment of marketing measures to quarantine situation please contact Legal Alliance Partner Oleksii Bezhevets: bezhevets@l-a.com.ua
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.